However, as the specific mechanism of Gal9 in GBM remains unclear, an in‐depth study of the biological processes of Gal9 in antitumor immunity will provide a molecular basis for targeted Gal9 therapy. This evidence concerns the gene LGALS9 and glioblastoma.